These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28971773)

  • 1. Development, Potential Anticancer Activity and the Receptor Profile of Different Functionalized 1,3,5-Triazine Derivatives.
    Sarhan MO; Motaleb MA; Ibrahim IT; Anwar MM; Zaghary WA
    Mini Rev Med Chem; 2018; 18(15):1302-1320. PubMed ID: 28971773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors.
    Oudah KH; Najm MAA; Samir N; Serya RAT; Abouzid KAM
    Bioorg Chem; 2019 Nov; 92():103239. PubMed ID: 31513938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,2,4-triazine analogs as novel class of therapeutic agents.
    Kumar R; Sirohi TS; Singh H; Yadav R; Roy RK; Chaudhary A; Pandeya SN
    Mini Rev Med Chem; 2014 Feb; 14(2):168-207. PubMed ID: 24479860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
    Zhou X; Lin K; Ma X; Chui WK; Zhou W
    Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,3,5-Triazines: A promising scaffold for anticancer drugs development.
    Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
    Eur J Med Chem; 2017 Dec; 142():523-549. PubMed ID: 29046238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,3,5-Triazine-based analogues of purine: from isosteres to privileged scaffolds in medicinal chemistry.
    Lim FP; Dolzhenko AV
    Eur J Med Chem; 2014 Oct; 85():371-90. PubMed ID: 25105925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the hydrophobic region of Hsp90's ATP binding pocket with novel 1,3,5-triazines.
    Lee T; Seo YH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6427-31. PubMed ID: 24125885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds.
    Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
    Eur J Med Chem; 2017 Dec; 142():328-375. PubMed ID: 28851503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Privileged s-triazines: structure and pharmacological applications.
    Shah DR; Modh RP; Chikhalia KH
    Future Med Chem; 2014 Mar; 6(4):463-77. PubMed ID: 24635525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer drug discovery targeting DNA hypermethylation.
    Yu N; Wang M
    Curr Med Chem; 2008; 15(14):1350-75. PubMed ID: 18537614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Activity of s-Triazine Derivatives: A Systematic Review.
    Dai Q; Sun Q; Ouyang X; Liu J; Jin L; Liu A; He B; Fan T; Jiang Y
    Molecules; 2023 May; 28(11):. PubMed ID: 37298753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Biological Evaluation of Novel Nonsteroidal Progesterone Receptor Antagonists Based on Phenylamino-1,3,5-triazine Scaffold.
    Kaitoh K; Nakatsu A; Mori S; Kagechika H; Hashimoto Y; Fujii S
    Chem Pharm Bull (Tokyo); 2019; 67(6):566-575. PubMed ID: 31155562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors.
    Dutta Gupta S; Bommaka MK; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM
    Int J Biol Macromol; 2015 Sep; 80():253-9. PubMed ID: 26116388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives.
    Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
    Eur J Med Chem; 2017 Dec; 142():74-86. PubMed ID: 28615111
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Dubey P; Pathak DP; Ali F; Chauhan G; Kalaiselvan V
    Curr Drug Discov Technol; 2024; 21(2):e170723218813. PubMed ID: 37461340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Methyltransferase 3A: A Significant Target for the Discovery of Inhibitors as Potent Anticancer Drugs.
    Feng Q; Duan H; Zhou X; Wang Y; Zhang J; Zhang H; Chen G; Bao X
    Mini Rev Med Chem; 2024; 24(5):507-520. PubMed ID: 37642180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery.
    Napper AD
    IDrugs; 2010 Jun; 13(6):372-5. PubMed ID: 20506057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.